

1

2

- ١,
- 1 2
- 1 2
- 1
- 1 2

3

1

2

1 2

1 2

3

2
3

- 2. (Once Amended) The device of claim 1, wherein the tubular elongate member is comprised of a porous synthetic material.
- 3. (Once Amended) The device of claim 2, wherein the porous synthetic material is polytetrafluoroethylene (PTFE), dacron or nylon.
- 4. (Once Amended) The device of claim 3, wherein the tubular elongate member is a vascular graft.
- 5. (Once Amended) The device of claim 1, wherein the autologous vascular smooth muscle cells are transduced with a gene encoding erythropoietin.

(Twice Amended) The device of claim 1, wherein the autologous vascular smooth muscle cells are transduced with a gene encoding granulocyte colony stimulating factor or granulocyte macrophage colony stimulating factor.

- 7. (Twice Amended) The device of claim 1, wherein the autologous vascular smooth muscle cells are transduced with a gene encoding Factor IX.
- 8. (Twice Amended) the device of claim 1, wherein the transduced autologous vascular smooth muscle cells express an anticoagulant.

(Once Amended) The device of claim 1, wherein the transduced autologous vascular smooth muscle cells are immobilized to the tubular elongate member with a polymer.

10. (Twice Amended) The device of claim 1, wherein the device, prior to implantation in a subject, further comprises autologous vascular endothelial cells adherent to an interior surface of the tubular smooth muscle cell complex.

11. (Thrice Amended) A method for preparing a vascular graft seeded ex vivo with vascular smooth muscle cells transduced to express a gene of interest, comprising the steps of:

transducing mammalian vascular smooth muscle cells with the gene of interest operably linked to a promoter for expression;

and immobilizing the transduced vascular smooth muscle cells on a vascular graft surface, whereby the smooth muscle cells remain stably immobilized on the graft surface and express a product of said gene, thereby producing said vascular graft having vascular smooth muscle cells transduced to express a gene of interest.

- 12. (Once Amended) The method of claim 11, wherein the gene encodes erythropoietin, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, or Factor IX.
- 13. (Thrice Amended) The method of claim 11, wherein the gene encodes erythropoietin.
- 14. (Thrice Amended) The method claim 11, wherein the gene encodes Factor IX.
- 15. (Thrice Amended) The method of claim 11, wherein the gene encodes granulocyte colony stimulating factor or granulocyte macrophage colony stimulating factor.
- 16. (Thrice Amended) The method of claim 11, wherein the transduced cells constitutively express an anticoagulant protein.
- 17. (Once Amended) The method of claim 16, wherein the anticoagulant is a plasminogen activator or antithrombin-III.

1 2

 18. (Once Amended) The method of claim 17, wherein the plasminogen activator is alteplase or urokinase.

- 19. (Four Times Amended) The method of claim 11, wherein the gene of interest encodes insulin or proinsulin polypeptide, and wherein the transduced cells express insulin or proinsulin polypeptide.
- 20. (Thrice Amended) A method for preparing a vascular graft device seeded ex vivo with vascular smooth muscle cells transduced to express a protein product, comprising the steps of:

culturing vascular endothelial cells and vascular smooth muscle cells obtained from a mammalian subject;

transducing the smooth muscle cells with a gene which encodes the protein product, operably linked to a promotor;

immobilizing on a tubular elongate porous vascular graft device the transduced smooth muscle cells within the pores and interior surface of the graft device; and coating the interior of the graft device having immobilized thereon the transduced smooth muscle cells with the endothelial cells.

- 21. (Thrice Amended) The method of claim 20, further comprising the step of culturing the vascular smooth muscle cells obtained from a mammalian subject in a medium containing autologous serum prior to immobilizing the cells on the vascular graft device.
- 22. (Twice Amended) The method of claim 21, further comprising the step of culturing the vascular endothelial cells obtained from a mammalian subject in a medium containing autologous serum prior to coating the vascular graft device.